Aripiprazole versus other atypical antipsychotics for schizophrenia

Abstract

Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials.

Family Support and Adherence to Treatment in Patients Diagnosed with Schizophrenia in Tabasco, Mexico: A Case- Series Study

“…The likelihood of causing extrapyramidal symptom with second-generation antipsychotics also exists and depends on many factors, viz. : characteristics of the patient (age, gender, and concomitant conditions), history of the disease, previous treatment, choice of a particular antipsychotic, dose, duration of treatment, and adjuvant therapy [29,30]. Therefore, all these elements must be taken into consideration to minimize the risk of extrapyramidal symptoms and provide the best quality of care [29].…”

Second-Generation Antipsychotics Clinical Pharmacy Plan Developed from Hospital Pharmacy to Primary Health Care

“…The supply chain management will be agreed in each case between the Hospital Pharmacy Department and the corresponding Primary Healthcare, taking into account the population served [10][11][12]. The qualitative content collected for each SGA.…”

Extrapyramidal Symptoms in Patients Treated with Antipsychotic Drugs

“…Aripiprazole exerts a partial D2 agonistic effect, a 5-HT2A antagonistic effect and a 5-HT1A agonistic effect. It shows good antipsychotic properties and seldom causes EPS [18]. Cariprazine is a new SGA with a partial agonistic effect at the D2 and D3 receptors.…”